IPO: TC BioPharm (Holdings) plc Date: 11 February 2022

Symbol: TCBP
Industry: Biotechnology
Exchange: NASDAQ
IPO Price Low: $7
IPO Price High: $9

TCB is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulations, with a view to launching its first oncology product, which will be for the treatment of acute myeloid leukemia (abbreviated as AML). The Company plans to conduct similar clinical trials in the United States in 2022 for the treatment of AML following an application to the FDA in H1 2022. Clinical results generated thus far have enabled TCB to obtain FDA orphan drug status for its method of treatment of AML. TCB is also developing an innovative range of genetically modified chimeric antigen receptor modified T cell (CAR-T) products for treatment of solid cancers.

Shares Offered: 4117648
Shares Outstanding: 28058398
Market Cap: 119248191

How to buy TC BioPharm (Holdings) plc stock

For more information on the TC BioPharm (Holdings) plc IPO please sign up using the form opposite.

IPO Exchange is dedicated to providing accurate information to help you make the best investment decisions and expand your portfolio.

Get more details on how you can invest in TC BioPharm (Holdings) plc by signing up below.